Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes
Abstract Aims/Introduction Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are used worldwide because of their multiple benefits for patients with type 2 diabetes. The purpose of this study was to determine the efficacy and safety of SGLT2i in patients with type 1 diabetes. Materials and Methods...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-02-01
|
| Series: | Journal of Diabetes Investigation |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/jdi.13335 |
| _version_ | 1818962486432366592 |
|---|---|
| author | Koki Chiba Hiroshi Nomoto Akinobu Nakamura Kyu Yong Cho Kumiko Yamashita Yui Shibayama Aika Miya Hiraku Kameda Yoshio Kurihara Shin Aoki Tatsuya Atsumi Hideaki Miyoshi |
| author_facet | Koki Chiba Hiroshi Nomoto Akinobu Nakamura Kyu Yong Cho Kumiko Yamashita Yui Shibayama Aika Miya Hiraku Kameda Yoshio Kurihara Shin Aoki Tatsuya Atsumi Hideaki Miyoshi |
| author_sort | Koki Chiba |
| collection | DOAJ |
| description | Abstract Aims/Introduction Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are used worldwide because of their multiple benefits for patients with type 2 diabetes. The purpose of this study was to determine the efficacy and safety of SGLT2i in patients with type 1 diabetes. Materials and Methods Patients with type 1 diabetes who had been treated with SGLT2i for >12 weeks were included in this retrospective observation study. We recorded the changes in body mass, insulin dose, blood and urine test data, and adverse events. The changes in day‐to‐day glucose variability, as the primary end‐point, was evaluated using the interquartile range (P25/P75) of the ambulatory glucose data obtained using continuous glucose monitoring. Results A total of 51 patients (37 women; mean age 52.7 years) were included. Glycated hemoglobin and body mass significantly decreased by 0.4% and 1.6 kg, respectively. The total required insulin dose decreased by 9.4% (42.7 ± 26.6–38.7 ± 24.3 units/day). Continuous glucose monitoring data were obtained from 30 patients. P25/P75 decreased by 17.6 ± 20.7% during SGLT2i treatment (P < 0.001). The percentage of time per day within the target glucose range of 70–180 mg/dL significantly increased (from 42.2 to 55.5%, P < 0.001), without an increase in the percentage of time spent in the hypoglycemic range (<70 mg/dL). Urinary ketone bodies were detected in four patients (7.8%), but none developed ketoacidosis. Conclusions SGLT2i improved day‐to‐day glucose variability and time in the target glucose range, without increasing frequency of hypoglycemia, in patients with type 1 diabetes, and reduced glycated hemoglobin, body mass and the required insulin dose. |
| first_indexed | 2024-12-20T12:30:05Z |
| format | Article |
| id | doaj.art-1dbe280944994136a7b013586e954b51 |
| institution | Directory Open Access Journal |
| issn | 2040-1116 2040-1124 |
| language | English |
| last_indexed | 2024-12-20T12:30:05Z |
| publishDate | 2021-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Investigation |
| spelling | doaj.art-1dbe280944994136a7b013586e954b512022-12-21T19:40:45ZengWileyJournal of Diabetes Investigation2040-11162040-11242021-02-0112217618310.1111/jdi.13335Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetesKoki Chiba0Hiroshi Nomoto1Akinobu Nakamura2Kyu Yong Cho3Kumiko Yamashita4Yui Shibayama5Aika Miya6Hiraku Kameda7Yoshio Kurihara8Shin Aoki9Tatsuya Atsumi10Hideaki Miyoshi11Department of Rheumatology, Endocrinology and Nephrology Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo JapanDepartment of Rheumatology, Endocrinology and Nephrology Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo JapanDepartment of Rheumatology, Endocrinology and Nephrology Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo JapanDepartment of Rheumatology, Endocrinology and Nephrology Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo JapanKurihara Clinic Sapporo JapanDepartment of Rheumatology, Endocrinology and Nephrology Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo JapanDepartment of Rheumatology, Endocrinology and Nephrology Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo JapanDepartment of Rheumatology, Endocrinology and Nephrology Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo JapanKurihara Clinic Sapporo JapanAoki Clinic Sapporo JapanDepartment of Rheumatology, Endocrinology and Nephrology Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo JapanDepartment of Rheumatology, Endocrinology and Nephrology Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo JapanAbstract Aims/Introduction Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are used worldwide because of their multiple benefits for patients with type 2 diabetes. The purpose of this study was to determine the efficacy and safety of SGLT2i in patients with type 1 diabetes. Materials and Methods Patients with type 1 diabetes who had been treated with SGLT2i for >12 weeks were included in this retrospective observation study. We recorded the changes in body mass, insulin dose, blood and urine test data, and adverse events. The changes in day‐to‐day glucose variability, as the primary end‐point, was evaluated using the interquartile range (P25/P75) of the ambulatory glucose data obtained using continuous glucose monitoring. Results A total of 51 patients (37 women; mean age 52.7 years) were included. Glycated hemoglobin and body mass significantly decreased by 0.4% and 1.6 kg, respectively. The total required insulin dose decreased by 9.4% (42.7 ± 26.6–38.7 ± 24.3 units/day). Continuous glucose monitoring data were obtained from 30 patients. P25/P75 decreased by 17.6 ± 20.7% during SGLT2i treatment (P < 0.001). The percentage of time per day within the target glucose range of 70–180 mg/dL significantly increased (from 42.2 to 55.5%, P < 0.001), without an increase in the percentage of time spent in the hypoglycemic range (<70 mg/dL). Urinary ketone bodies were detected in four patients (7.8%), but none developed ketoacidosis. Conclusions SGLT2i improved day‐to‐day glucose variability and time in the target glucose range, without increasing frequency of hypoglycemia, in patients with type 1 diabetes, and reduced glycated hemoglobin, body mass and the required insulin dose.https://doi.org/10.1111/jdi.13335Glucose variabilitySodium–glucose cotransporter 2 inhibitorType 1 diabetes |
| spellingShingle | Koki Chiba Hiroshi Nomoto Akinobu Nakamura Kyu Yong Cho Kumiko Yamashita Yui Shibayama Aika Miya Hiraku Kameda Yoshio Kurihara Shin Aoki Tatsuya Atsumi Hideaki Miyoshi Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes Journal of Diabetes Investigation Glucose variability Sodium–glucose cotransporter 2 inhibitor Type 1 diabetes |
| title | Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes |
| title_full | Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes |
| title_fullStr | Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes |
| title_full_unstemmed | Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes |
| title_short | Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes |
| title_sort | sodium glucose cotransporter 2 inhibitors reduce day to day glucose variability in patients with type 1 diabetes |
| topic | Glucose variability Sodium–glucose cotransporter 2 inhibitor Type 1 diabetes |
| url | https://doi.org/10.1111/jdi.13335 |
| work_keys_str_mv | AT kokichiba sodiumglucosecotransporter2inhibitorsreducedaytodayglucosevariabilityinpatientswithtype1diabetes AT hiroshinomoto sodiumglucosecotransporter2inhibitorsreducedaytodayglucosevariabilityinpatientswithtype1diabetes AT akinobunakamura sodiumglucosecotransporter2inhibitorsreducedaytodayglucosevariabilityinpatientswithtype1diabetes AT kyuyongcho sodiumglucosecotransporter2inhibitorsreducedaytodayglucosevariabilityinpatientswithtype1diabetes AT kumikoyamashita sodiumglucosecotransporter2inhibitorsreducedaytodayglucosevariabilityinpatientswithtype1diabetes AT yuishibayama sodiumglucosecotransporter2inhibitorsreducedaytodayglucosevariabilityinpatientswithtype1diabetes AT aikamiya sodiumglucosecotransporter2inhibitorsreducedaytodayglucosevariabilityinpatientswithtype1diabetes AT hirakukameda sodiumglucosecotransporter2inhibitorsreducedaytodayglucosevariabilityinpatientswithtype1diabetes AT yoshiokurihara sodiumglucosecotransporter2inhibitorsreducedaytodayglucosevariabilityinpatientswithtype1diabetes AT shinaoki sodiumglucosecotransporter2inhibitorsreducedaytodayglucosevariabilityinpatientswithtype1diabetes AT tatsuyaatsumi sodiumglucosecotransporter2inhibitorsreducedaytodayglucosevariabilityinpatientswithtype1diabetes AT hideakimiyoshi sodiumglucosecotransporter2inhibitorsreducedaytodayglucosevariabilityinpatientswithtype1diabetes |